| EN
We are rapidly transitioning to an innovation and R&D-driven pharmaceutical company, with a mission of “providing today’s patients with medicines of the future.” We focus on oncology, central nervous system disease and autoimmune disease therapeutic areas.We have established R&D centers in Shanghai, Nanjing and Boston. With the approval of the Ministry of Science and Technology, we have also established a National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals . We have been continuously recognized as one of the “Top 10 Innovative Pharmaceutical Enterprises in China” and “Top 100 Pharmaceutical Manufacturing Enterprises of China ”. We were listed on the Hong Kong Stock Exchange in 2020.

Milestones

  • 1995

  • 2001

  • 2003

  • 2007

  • 2015

  • 2018

  • 2019

  • 2020

  • Established Jiangsu Simcere, engaging in the sales, marketing and distribution of pharmaceuticals

  • Acquired a controlling interest in Hainan Simcere and manufacturing capabilities of pharmaceuticals,
    built our own research and development team

  • Acquired the entire equity interest in Simcere, which further enriched its product portfolio and production capabilities

  • Was listed on the NYSE on April 20, 2007, making it the first bio and chemical pharmaceutical company in China to be listed on the NYSE, privatization was completed in 2013

  • Established the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals approved by the Ministry of Science and Technology

  • Shanghai R&D center established

  • Boston R&D Center established

  • Listed on the Hong Kong Stock Exchange (02096.HK)

  • Established Jiangsu Simcere, engaging in the sales, marketing and distribution of pharmaceuticals
  • Cquired a controlling interest in Hainan Simcere and manufacturing capabilities of pharmaceuticals, built our own research and development team
  • Acquired the entire equity interest in Simcere, which further enriched its product portfolio and production capabilities
  • Was listed on the NYSE on April 20, 2007, making it the first bio and chemical pharmaceutical company in China to be listed on the NYSE, privatization was completed in 2013
  • Established the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals approved by the Ministry of Science and Technology
  • Shanghai R&D center established
  • Boston R&D Center established
  • Listed on the Hong Kong Stock Exchange (02096.HK)

Management Team

Mission

Providing Today’s Patients with Medicines of the Future

Core Values

Integrity
Excellence
Perseverance
Proactivity
Customer-First

Simcere CI

  • The name “Simcere” comes from the word “sincere”, which embodies our main principle of treating people with sincerity.
  • On the left side of our logo is Simcerer running against the wind, representing the spirit of unremitting endeavor and the encourage to pursue excellence.
  • The color green symbolizes life, health and vitality.